Tozorakimab, Tozorakimab-placebo
D9185C00001
Phase 3 small_molecule active
Quick answer
Tozorakimab, Tozorakimab-placebo for Severe viral lung infections is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Severe viral lung infections
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active